<Anchor> Since



all vaccines are imported from different countries, there are sometimes variations in the supply schedule. Therefore, it is most important for Korea to make its own vaccine, and a domestic pharmaceutical company has started a phase 3 clinical trial for the first coronavirus vaccine.



Including this, 10 vaccines are currently undergoing clinical trials in Korea, and medical reporter Cho Dong-chan took a closer look at what stage they have reached.



<Reporter> The



Ministry of Food and Drug Safety has approved the phase 3 clinical trial for the COVID-19 vaccine developed by SK Bioscience.



This is because safety and efficacy were confirmed in Phase 1 clinical trials on 80 adults.



[Kim Kang-lip / Minister of Food and Drug Safety: (Phase 3 clinical trial) The subjects of the test are 3,990 adults over the age of 18.]



What is unusual is that it is a comparative clinical trial.



Originally, it was to calculate how much less people who got the real vaccine get COVID-19 than people who got the fake vaccine, and it compares the effectiveness with the AstraZeneca vaccine instead of the fake vaccine.



This is because it is difficult to find test subjects for tens of thousands of people who can get fake vaccines as vaccinations are in full swing around the world.



Although the exact prevention rate cannot be calculated, the clinical trial period can be shortened.



[Kim Kang-lip / Minister of Food and Drug Safety: 3,000 people for the test vaccine (SK Bioscience) and 990 people for the control vaccine (AstraZeneca) will be vaccinated twice at 4 week intervals.]



However, the comparative clinical trial is the second in the world, and there is no case of approval for use.



Phase 3 interim results will be announced in the first quarter of next year, with the goal of commercialization within the first half of next year.



There are currently 10 clinical vaccines for COVID-19 in Korea.



The DNA vaccine, which started clinical trials last year, is currently in phase 1 and phase 2, but we need to see more results to see if there are enough neutralizing antibodies.



One company did not have enough neutralizing antibodies.



mRNA vaccines such as Pfizer and Moderna were also approved for phase 1 clinical trials last month.



The self-amplification method can boost immunity more than conventional vaccines, but for humans, this is the first step.



Like Novavax in the US, there are five vaccines with recombinant protein, the most, and the most advanced neutralizing antibody of SK Bioscience was five times higher than that of a cured person.



There are 132 coronavirus vaccines in clinical trials worldwide, and 33 have completed phase 3 clinical trials.



However, only 11 have received emergency approval.



Indigenous vaccines in Korea, the path that must be taken, but premature optimism must be guarded against.



(Video coverage: Kim Min-cheol, Video editing: Kim Jun-hee, CG: Ryu Sang-su, Seo Hyun-joong)